All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Roche out-licenses GLP-1/GIP agonist CT-388 to Chugai for Japan diabetes/obesity development
Licensing deal, small molecule, metabolic disorders, milestone payments - Read more

THE GOOD
Clinical Trials

Regeneron reports updated Ph1/2 data for DB-OTO gene therapy treating genetic hearing loss in children
Gene therapy, neurological, AAV gene therapy, hearing loss, DFNB9, synaptic transmission - Read more

Satellos reports Ph1 efficacy for oral SAT-3247 targeting AAK1 in Duchenne muscular dystrophy, plans Ph2 trial
Small molecule, neurological, Duchenne muscular dystrophy, AAK1 inhibitor, muscle regeneration - Read more

Taiho, Cullinan present Ph2 zipalertinib data for EGFR-mutated non-small cell lung cancer with brain metastases
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, EGFR mutations, brain metastases - Read more

Arcus reports 26.7-month median survival for domvanalimab plus zimberelimab in Ph2 gastroesophageal adenocarcinoma trial
Antibody, cancer, monoclonal antibody, gastroesophageal adenocarcinoma, TIGIT target, combination therapy - Read more

Assembly Biosciences reports Ph1b data for ABI-5366 helicase-primase inhibitor showing 94% reduction in herpes simplex virus shedding
Small molecule, infectious disease, helicase-primase inhibitor, herpes simplex virus, HSV-2 - Read more

OS Therapies' OST-HER2 HER2-targeting vaccine shows significant Ph2 survival improvement in recurrent pulmonary metastatic osteosarcoma patients
Vaccine, cancer, cancer vaccine, osteosarcoma, HER2 target, immunotherapy - Read more

Cabaletta's resecabtagene autoleucel CAR-T eliminates B cells without preconditioning in Ph1/2 pemphigus vulgaris trial
Cell therapy, autoimmune, CAR-T, pemphigus vulgaris, B cell depletion, no preconditioning - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Fundraises

Evommune files IPO to advance inflammatory condition treatments through Phase 2
Autoimmune, small molecule, clinical-stage, chronic inflammatory conditions - Read more

Quoin Pharmaceuticals raises $104.5M private placement, rare and orphan diseases specialty pharma
Rare disease, specialty pharmaceutical, clinical-stage, orphan diseases - Read more

Samsara BioCapital plans to raise a $200M opportunity fund, supporting existing life sciences portfolio companies
Investment firm, life sciences - Read more

Idorsia raises $65M equity offering, funding QUVIVIQ commercialization and pipeline advancement
Small molecule, neurological, commercial-stage, sleep disorders - Read more

THE GOOD
Investments

Ypsomed invests $248M to build first U.S. auto-injector manufacturing facility in North Carolina
Drug delivery device, diabetes/metabolic, strategic, major investment, operational, manufacturing expansion - Read more

THE GOOD
Mergers & Acquisitions

Bristol Myers Squibb acquires Orbital Therapeutics for $1.5B to advance in vivo cell therapy technology
In vivo cell therapy, autoimmune, strategic, major transaction - Read more

Shuttle Pharmaceuticals acquires Molecule.ai for $10M to enter AI-driven drug discovery market
AI drug discovery platform, oncology, strategic, major transaction - Read more

Johnson & Johnson in acquisition talks with immunology partner Protagonist Therapeutics, potentially valuing company above $4B
Oral peptide, autoimmune, strategic, major transaction - Read more

THE GOOD
Politics & Policy

AstraZeneca joins Trump's MFN pricing program, offering Medicaid drugs at global lowest prices
Respiratory therapeutics, chronic disease, strategic, regulatory, major transaction, cost reduction - Read more

THE BAD
Layoffs

Novo Nordisk shuts cell therapy unit, cuts 250 jobs in $1.3B cost-saving restructuring plan
Cell therapy, diabetes, strategic, cost reduction, operational - Read more

THE BAD
Politics & Policy

MIT rejects White House funding deal requiring ideological compliance, citing scientific merit principles
Academic research, biotech funding, regulatory, strategic - Read more

Senate passes softer Biosecure Act successor targeting Chinese biotechs, notably excluding WuXi companies
Regulatory, strategic, operational, competitive - Read more

THE UGLY
Layoffs

Trump administration fires HHS employees during government shutdown, escalating beyond typical closure procedures
Regulatory, operational, strategic, government shutdown - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here